ADMA Biologics Inc

Good afternoon and welcome to the ADMA Biologics first quarter 2024 financial results and business update conference call on Thursday, May 9th, 2024. At this time, all participants are in a listen-only mode. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately two hours following the end of the call.

At this time, I would like to introduce Skylar Bloom. Please go ahead.

Welcome, everyone, and thank you for joining us this afternoon to discuss ADMA Biologics financial results for the first quarter of 2024 and recent corporate updates. I'm joined today by Adam Grossman, President and Chief Executive Officer and Interim Financial Officer, and Brad Tade, Vice President of Financial Operations. During today's call, Adam will provide some summary introductory comments and provide an update on corporate progress, and then Brad will provide an overview of the company's first quarter 2024 financial results. Finally, Adam will then provide some brief summary remarks before opening up the call for questions. Earlier today, we issued a press release detailing the first quarter 2024 financial results and summarized certain achievements in recent corporate updates. The release is available on our website, www.adminbiologics.com. Before we begin our formal comments, I'll remind you that we will be making forward-looking assertions during today's call that represent the company's intentions, expectations, or beliefs concerning future events, which constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to factors, risks, and uncertainties, such as those detailed in today's press release announcing this call and in our filings with the SEC, which may cause actual results to differ materially from the results expressed or implied by such statements. In addition, any forward-looking statements represent our views only as of the date of this call and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update any such statements, except as required by the federal securities laws. We refer you to the disclosure notice section in our earnings release we issued today in the risk factors section of our quarterly report on Form 10-Q for the quarter ended March 31st, 2024, for a discussion of the important risk factors that could cause actual results to differ materially from these forward-looking statements. Please note that the discussion on today's call includes certain non-GAAP financial measures, including adjusted EBITDA. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP metric is available in our earnings release. With that, I would now like to turn the call over to Adam Grossman. Adam, go ahead.